Microbiota-Dependent Marker TMAO Is Elevated in Silent Ischemia but Is Not Associated with First-Time Myocardial Infarction in HIV Infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 2, 2016, Pages 130-136

  Haissman, Judith M ^a   Knudsen, Andreas ^b,c   Hoel, Hedda ^d   Kjær, Andreas ^b   Kristoffersen, Ulrik S ^b   Berge, Rolf K ^e,f   Katzenstein, Terese L ^a   Svardal, Asbjørn ^e   Ueland, Thor ^g,h,i   Aukrust, Pål ^d,g,h,i   Lebech, Anne Mette ^c   Nielsen, Susanne D ^a   Trøseid, Marius ^d,g,h,i,j  

^a Department of Infectious Diseases ^*  (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Institute of Clinical Medicine   (Norway)

ⁱ KG Jebsen Inflammatory Research Center   (United States)

^j OSLO UNIVERSITY HOSPITAL   (Norway)

more..

Author keywords

ART; atherosclerosis; cardiovascular; coronary heart disease; HIV; ischemia; microbiota; myocardial infarction; protease inhibitor; TMAO

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLINE; PROTEINASE INHIBITOR; TRIMETHYLAMINE OXIDE; BIOLOGICAL MARKER; METHYLAMINE; TRIMETHYLAMINE; TRIMETHYLOXAMINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HEART MUSCLE PERFUSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; MYOCARDIAL PERFUSION DEFECT; PRIORITY JOURNAL; SILENT MYOCARDIAL ISCHEMIA; ADOLESCENT; ATHEROSCLEROTIC PLAQUE; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; CORONARY ARTERY DISEASE; HEART INFARCTION; ISCHEMIA; METABOLISM; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; ISCHEMIA; MALE; METHYLAMINES; MICROBIOTA; MIDDLE AGED; MYOCARDIAL INFARCTION; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS; YOUNG ADULT;

EID: 84955678290     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000843     Document Type: Article

References (38)

1. Triant VA. Epidemiology of coronary heart disease in patients with human immunodeficiency virus. Rev Cardiovasc Med. 2014;15(suppl 1):S1-S8.
2. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis. 2010;50:1387-1396.
3. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92:2506-2512.
4. So-Armah K, Freiberg MS. Cardiovascular disease risk in an aging HIV population: not just a question of biology. Curr Opin HIV AIDS. 2014;9: 346-354.
5. Silverberg MJ, Leyden WA, Xu L, et al. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care. J Acquir Immune Defic Syndr. 2014;65:160-166.
6. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173:614-622.
7. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453-468.
8. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep. 2012;9:139-147.
9. Zanni MV, Grinspoon SK. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep. 2012;9:200-205.
10. Stockmann M, Schmitz H, Fromm M, et al. Mechanisms of epithelial barrier impairment in HIV infection. Ann N Y Acad Sci. 2000;915:293-303.
11. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-1371.
12. Troseid M, Manner IW, Pedersen KK, et al. Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retro-viruses. 2014;30:514-522.
13. Latz E, Visintin A, Lien E, et al. Lipopolysaccharide rapidly traffics to and from the golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem. 2002;277:47834-47843.
14. da SB, Singer W, Fong IW, et al. In vivo cytokine and neuroendocrine responses to endotoxin in human immunodeficiency virus-infected subjects. J Infect Dis. 1999;180:106-115.
15. Lozupone CA, Rhodes ME, Neff CP, et al. HIV-induced alteration in gut microbiota: driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes. 2014;5:562-570.
16. Dinh DM, Volpe GE, Duffalo C, et al. Intestinal microbiota, microbial translocation, and systemic inflammation in chronic HIV infection. J Infect Dis. 2015;211:19-27.
17. Mutlu EA, Keshavarzian A, Losurdo J, et al. A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog. 2014;10:e1003829.
18. Vujkovic-Cvijin I, Dunham RM, Iwai S, et al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. 2013;5:193ra91.
19. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368: 1575-1584.
20. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011; 472:57-63.
21. Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124:4204-4211.
22. Ettinger G, MacDonald K, Reid G, et al. The influence of the human microbiome and probiotics on cardiovascular health. Gut Microbes. 2014;5:719-728.
23. Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576-585.
24. Bennett BJ, de Aguiar Vallim TQ, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17:49-60.
25. Wang Z, Tang WH, Buffa JA, et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethyl-amine-N-oxide. Eur Heart J. 2014;35:904-910.
26. Srinivasa S, Fitch KV, Lo J, et al. Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine. AIDS. 2015;29:443-452.
27. Kristoffersen US, Lebech AM, Wiinberg N, et al. Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: a case-control myocardial perfusion scintigraphy study. PLoS One. 2013; 8:e72066.
28. Knudsen A, Moller HJ, Katzenstein TL, et al. Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis. 2013;13:230.
29. Troseid M, Ueland T, Hov JR, et al. Microbiota-dependent metabolite trimethylamine-N-oxide is associated with disease severity and survival of patients with chronic heart failure. J Intern Med. 2015;277: 717-726.
30. Bjorndal B, Burri L, Wergedahl H, et al. Dietary supplementation of herring roe and milt enhances hepatic fatty acid catabolism in female mice transgenic for hTNFalpha. Eur J Nutr. 2012;51:741-753.
31. Backhed F. Meat-metabolizing bacteria in atherosclerosis. Nat Med. 2013;19:533-534.
32. Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64:1908-1914.
33. Tang WH, Wang Z, Shrestha K, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2015;21:91-96.
34. Sinha A, Ma Y, Carroll C. TMAO and HIV-Associated Atherosclerosis [Abstract]. In: Sinha A, Ma Y, Carroll C. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 1, 2015; Abstract No 755.
35. Kristoffersen US, Kofoed K, Kronborg G, et al. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med. 2009;10:79-87.
36. Zanni MV, Abbara S, Lo J, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS. 2013;27:1263-1272.
37. Koeth RA, Levison BS, Culley MK, et al. Gamma-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab. 2014;20:799-812.
38. Konstantinova SV, Tell GS, Vollset SE, et al. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr. 2008; 138:914-920.